Novel pharmacologic approaches to reduce bleeding

Canadian Journal of Anesthesia

Volumn 50, Issue 6 SUPPL., 2003, Pages

  Levy, Jerrold H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; APROTININ; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DESMOPRESSIN; DESMOPRESSIN ACETATE; FIBRINOGEN; HEPARIN; HEPARIN ANTAGONIST; HEPARIN LYASE; HIRULOG; KALLIKREIN; LOW MOLECULAR WEIGHT HEPARIN; LYSINE DERIVATIVE; PENTASACCHARIDE; PLACEBO; PROTAMINE; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; RECOMBINANT PROTEIN; RECOMBINANT THROMBOCYTE FACTOR 4; THROMBIN; TRANEXAMIC ACID; UNINDEXED DRUG;

ALLERGIC REACTION; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; BLEEDING; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG MECHANISM; HEART INFARCTION; HEART SURGERY; HEMOSTASIS; HUMAN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; ANTITHROMBINS; APROTININ; DEAMINO ARGININE VASOPRESSIN; HEMORRHAGE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; RECOMBINANT PROTEINS;

EID: 0042536453     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
2. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-6.
3. Turpie AGG, Weitz JI, Hirsh J. Advances in antithrombotic therapy: novel agents. Thromb Haemost 1995; 74: 565-71.
4. Dacecy LJ, Munoz JJ, Baribeau YR, et al. Rexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998; 133: 442-7.
5. Royston D, Kovesi T, Marczin N. The unwanted response to cardiac surgery: time for a reappraisal? J Thorac Cardiovasc Surg 2003; 125: 32-5.
6. Levy JH. Novel intravenous antithrombins. Am Heart J 2001; 141: 1043-7.
7. Willerson JT. Conversion from chronic to acute coronary heart disease syndromes: role of platelets and platelet products. Tex Heart Inst J 1995; 22: 13-9.
8. Mojcik C, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 2001; 71: 745-54.
9. Cicala C, Cirino G. Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sci 1998; 62: 1817-24.
10. Strukova SM, Dugina TN, Khgatian SV, Redkozubov AE, Redkozuba GP, Pinelis VG. Thrombin-mediated events implicated in mast cell activation. Semin Throm Hemost 1996; 22: 145.
11. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1995; 108(suppl): 258S-75S.
12. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
13. Danielsson A, Raub E, Lindahl U, Bjork I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261: 15467-73.
14. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076-82.
15. Despotis GJ, Joist JH, Hogue CW Jr, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902-8.
16. Mochizuki T, Olson PJ, Ramsay JG, Szlam F, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87: 781-5.
17. Levy JH. Hemostatic agents and their safety. J Cardiothorac Anesth 1999; 13(Suppl 1): 6-11.
18. Levy JH. Anaphylactic Reactions in Anesthesia and Intensive Care, 2nd ed. Butterworth-Heinemann; 1992.
19. Levy JH, Zaidan JR, Faraj BA. Prospective evaluation of risk of protamine reactions in NPH insulin-dependent diabetics. Anesth Analg 1986; 65: 739-42.
20. Levy JH, Cormack JG, Morales A. Heparin neutralization by platelet factor 4 and protamine. Anesth Analg 1995; 81: 35-7.
21. Slaughter TF, LeBleu TH, Douglas Jr JM, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994; 80: 520-6.
22. Zaidan JR, Johnson S, Brynes R, et al. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary atery surgery. Anesth Analg 1986; 65: 377-80.
23. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997; 85: 498-506.
24. Levy JH, Despotis GJ, Szlam F, Olson PJ, Meeker DP, Weisinger A. Recombinant human transgenic antithrombin in cardiac surgery: a dose finding study. Anesthesiology 2002; 96: 1095-102.
25. Levy JH, Weisinger A, Ziomek CA, Echelard Y. Recombinant antithrombin, production and role in cardiovascular disorders. Semin Thromb Hemost 2001; 27: 405-16.
26. Levy JH, Montes F, Szlam F, Hillyer C. In vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90: 1076-9.
27. Peters DC, Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs 1999; 57: 233-60.
28. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-53.
29. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354: 1940-7.
30. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: S715-20.
31. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994; 80: 1013-8.
32. Levy JH, Pifarre R, Schaff H, et al. A multicenter, placebo-controlled, double-blind trial of aprotinin to reduce blood loss and the requirement of donor blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92: 2236-44.
33. Alderman EL, Levy JH, Rich J, et al. Analysis of coronary graft patency after aprotinin use: results from the International multi-center aprotinin graft patency experience (IMAGE). J Thorac Cardiovasc Surg 1998; 116: 716-30.
34. Godet G, Bertrand M, Samama CM, et al. Aprotinin to decrease bleeding and intraoperative blood transfusion requirements during descending thoracic and thoracoabdominal aortic aneurysmectomy using cardiopulmonary bypass. Ann Vasc Surg 1994; 8: 452-6.
35. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. Lancet 2000; 355: 1303-9.
36. Janssens M, Joris J, David JL, et al. High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology 1994; 80: 23-9.
37. Murkin JM, Shannon NA, Bourne RB, et al. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth Analg 1995; 80: 343-8.
38. Murkin JM, Haig GM, Beer KJ, et al. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am 2000; 82: 675-84.
39. Capdevila X, Calvet Y, Biboulet P, et al. Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery. Anesthesiology 1998; 88: 50-7.
40. Hayes A, Murphy DB, McCarroll M. The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J Clin Anesth 1996; 8: 357-60.
41. Kasper SM, Elsner F, Hilgers D, et al. A retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. Eur J Anaesthesiol 1998; 15: 669-75.
42. Samama CM, Langeron O, Rosencher N, et al. Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study. Anesth Analg 2002; 95: 287-93.
43. Urban MK, Beckman J, Gordon M, Urquhart B, Boachie-Adjei O. The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. Spine 2001; 26: 1152-6.
44. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coag Fibrinolysis 2000; 11(Suppl 1): S107-11.
45. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
46. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-8.
47. Hedner U. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000; 26: 363.
48. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-93.
49. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26: 159-64.
50. Meijer K, de Graaff WE, Daenen SM, van der Meer J. Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa. Arch Intern Med 2000; 160: 2216-7.
51. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
52. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired IIb3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation Blood 2003; 101: 1864-70.
53. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113: 1930-7.
54. Slappendel R, Huvers FC, Benraad B, Novàkova I, van Hellemondt GG. Use of recombinant factor VIIa (NovoSeven®) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenias. Anesthesiology 2002; 96: 1525-7.
55. Svartholm E, Annerhagen V, Länne T. Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa (Letter). Anesthesiology 2002; 96: 1528.
56. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa (Letter). Lancet 1999; 354: 1879.
57. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-8.
58. Tanaka KA, Waly A, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah's witness patients after cardiac surgery with recombinant activated Factor VII (NovoSeven®). Anesthesiology (in press).
59. Al Douri M, Shafi T, Al Khudairi D, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S121-7.
60. Zietkiewicz M, Garlicki M, Domagala J, et al. Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg 2002; 123: 384-5.
61. Sheth S, Dimichele D, Lee M, et al. Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa. Haemophilia 2001; 7: 227-32.
62. Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant Factor VII (case report). Anesth Analg 2001; 93: 287-9.